DexCom, Inc.
DXCM
Peringkat dalam Saham
#757
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Harga Saham
$85.72
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$32.35B
Perubahan (1 hari)
-0.30%
Perubahan (1 tahun)
22.90%
Negara
US
Perdagangan DexCom, Inc. (DXCM)
Kategori
Healthcare
Rasio P/E untuk DexCom, Inc. (DXCM)
Rasio P/E per October 2026 TTM: 32.23
Menurut laporan keuangan dan harga saham terbaru dari DexCom, Inc., rasio P/E saat ini (TTM) adalah 32.23. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar 88.46.
Riwayat rasio P/E untuk DexCom, Inc. dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 32.23 | -40.99% |
| 2024 | 54.61 | -38.26% |
| 2023 | 88.46 | -31.56% |
| 2022 | 129.24 | -46.03% |
| 2021 | 239.45 | 238.65% |
| 2020 | 70.71 | -64.13% |
| 2019 | 197.12 | -337.11% |
| 2018 | -83.13 | -15.75% |
| 2017 | -98.68 | 29.66% |
| 2016 | -76.11 | -32.94% |
| 2015 | -113.49 | -38.58% |
| 2014 | -184.78 | 118.77% |
| 2013 | -84.46 | 392.67% |
| 2012 | -17.14 | 25.47% |
| 2011 | -13.66 | -2.87% |
| 2010 | -14.07 | 110.14% |
| 2009 | -6.69 | 353.93% |
| 2008 | -1.47 | -72.97% |
| 2007 | -5.46 | -5.53% |
| 2006 | -5.77 | -37.14% |
| 2005 | -9.19 | 376.58% |
| 2004 | -1.93 | -25.11% |
| 2003 | -2.57 | -17.56% |
| 2002 | -3.12 | -12.19% |
| 2001 | -3.56 | -30.59% |
| 2000 | -5.12 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 33.11 | 2.74% |
US
|
|
| 21.39 | -33.64% |
IE
|
|
| 28.94 | -10.19% |
US
|
|
| 17.34 | -46.20% |
US
|
|
| - | - |
DE
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.